Swiss National Bank reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 10.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 454,800 shares of the biopharmaceutical company’s stock after selling 53,200 shares during the quarter. Swiss National Bank owned approximately 0.16% of Amicus Therapeutics worth $5,044,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Van ECK Associates Corp increased its position in Amicus Therapeutics by 48.9% during the 4th quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 981 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Amicus Therapeutics by 33.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,807 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 953 shares during the period. First Horizon Advisors Inc. grew its position in shares of Amicus Therapeutics by 37.3% in the 4th quarter. First Horizon Advisors Inc. now owns 3,856 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 1,048 shares during the period. Parallel Advisors LLC grew its position in shares of Amicus Therapeutics by 72.4% in the 4th quarter. Parallel Advisors LLC now owns 6,099 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 2,562 shares during the period. Finally, Point72 Middle East FZE purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $81,000.
Insider Buying and Selling at Amicus Therapeutics
In other news, CAO Samantha Prout sold 36,909 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $14.01, for a total value of $517,095.09. Following the transaction, the chief accounting officer now owns 137,003 shares in the company, valued at approximately $1,919,412.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 8,300 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $12.50, for a total transaction of $103,750.00. Following the sale, the chief executive officer now owns 815,154 shares in the company, valued at approximately $10,189,425. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Samantha Prout sold 36,909 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $14.01, for a total transaction of $517,095.09. Following the sale, the chief accounting officer now owns 137,003 shares in the company, valued at approximately $1,919,412.03. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,629 shares of company stock worth $1,445,385. Company insiders own 2.10% of the company’s stock.
Analyst Ratings Changes
Amicus Therapeutics Price Performance
FOLD opened at $13.15 on Thursday. The company has a debt-to-equity ratio of 3.53, a quick ratio of 2.40 and a current ratio of 2.72. The stock has a market capitalization of $3.78 billion, a P/E ratio of -20.55 and a beta of 0.84. The company’s 50-day simple moving average is $12.93 and its two-hundred day simple moving average is $12.26. Amicus Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $14.10.
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $89.57 million. Amicus Therapeutics had a negative net margin of 52.85% and a negative return on equity of 157.79%. As a group, analysts predict that Amicus Therapeutics, Inc. will post -0.43 EPS for the current year.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Five stocks we like better than Amicus Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- How to Buy Gold Stock and Invest in Gold
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.